- Home
- TRVI vs PRA Comparison
TRVI vs PRA Comparison
Compare TRVI & PRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- PRA
- Stock Information
- Founded
- TRVI 2011
- PRA 1976
- Country
- TRVI United States
- PRA United States
- Employees
- TRVI N/A
- PRA N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- PRA Property-Casualty Insurers
- Sector
- TRVI Health Care
- PRA Finance
- Exchange
- TRVI Nasdaq
- PRA Nasdaq
- Market Cap
- TRVI 1.1B
- PRA 1.2B
- IPO Year
- TRVI 2019
- PRA N/A
- Fundamental
- Price
- TRVI $10.65
- PRA $24.05
- Analyst Decision
- TRVI Strong Buy
- PRA Hold
- Analyst Count
- TRVI 9
- PRA 4
- Target Price
- TRVI $20.72
- PRA $21.00
- AVG Volume (30 Days)
- TRVI 2.0M
- PRA 432.2K
- Earning Date
- TRVI 11-05-2025
- PRA 11-06-2025
- Dividend Yield
- TRVI N/A
- PRA N/A
- EPS Growth
- TRVI N/A
- PRA N/A
- EPS
- TRVI N/A
- PRA 0.95
- Revenue
- TRVI N/A
- PRA $1,128,928,000.00
- Revenue This Year
- TRVI N/A
- PRA N/A
- Revenue Next Year
- TRVI N/A
- PRA N/A
- P/E Ratio
- TRVI N/A
- PRA $25.29
- Revenue Growth
- TRVI N/A
- PRA N/A
- 52 Week Low
- TRVI $2.36
- PRA $13.00
- 52 Week High
- TRVI $11.11
- PRA $24.22
- Technical
- Relative Strength Index (RSI)
- TRVI 71.22
- PRA 58.25
- Support Level
- TRVI $9.29
- PRA $23.90
- Resistance Level
- TRVI $10.04
- PRA $24.07
- Average True Range (ATR)
- TRVI 0.57
- PRA 0.10
- MACD
- TRVI 0.07
- PRA -0.01
- Stochastic Oscillator
- TRVI 82.67
- PRA 45.31
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.